4AB.DE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:35):

Stats
Šios dienos apimtis	757.00
Vidutinė apimtis	707.00
Rinkos kapitalizacija	263.61B
EPS	€0 ( 2024-04-26 )
Kita pelno data	( €0 ) 2024-07-24
Last Dividend	€1.480 ( 2023-07-13 )
Next Dividend	€0 ( N/A )
P/E	47.57
ATR14	€0.491 (0.33%)

Abbvie Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Abbvie Inc Finansinės ataskaitos

Annual	2023
Pajamos:	€54.32B
Bruto pelnas:	€33.90B (62.42 %)
EPS:	€2.75

FY	2023
Pajamos:	€54.32B
Bruto pelnas:	€33.90B (62.42 %)
EPS:	€2.75

FY	2022
Pajamos:	€58.05B
Bruto pelnas:	€40.64B (70.00 %)
EPS:	€6.69

FY	2021
Pajamos:	€56.20B
Bruto pelnas:	€38.75B (68.96 %)
EPS:	€6.92

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€1.410 (N/A)	€1.410 (N/A)	€1.480 (N/A)	€1.480 (N/A)	€1.480 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Abbvie Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.84 - low (60.66%) | Divividend Growth Potential Score: 6.92 - Stable (38.35%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.570	2016-07-13
Last Dividend	€1.480	2023-07-13
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	€24.73	--
Avg. Dividend % Per Year	0.00%	--
Score	3.49	--
Div. Sustainability Score	4.84
Div.Growth Potential Score	6.92
Div. Directional Score	5.88	--

Next Divdend (Est)
(2024-07-31)

€0 Estimate 20.17 %

Dividend Stability

0.54 Average

Dividend Score

3.49

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PSQ.F	Ex Dividend Knight	2023-08-23	Semi-Annually	0.00%
BC8.DE	Ex Dividend Knight	2023-05-26	Annually	0.00%
IBE1.DE	Ex Dividend Knight	2023-07-07	Semi-Annually	0.00%
ST5.DE	No Dividend Player	2023-06-26	Annually	0.00%
COP.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
LHOG.F	Ex Dividend Junior	2023-08-24	Semi-Annually	0.00%
V6C.DE	Ex Dividend Junior	2023-06-01	Annually	0.00%
EBO.DE	Ex Dividend Junior	2023-05-16	Annually	0.00%
NOEJ.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
ABR.DE	Ex Dividend Knight	2023-08-30	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.110	1.500	7.80	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.524	1.500	5.28	7.93	[0.1 - 1]
payoutRatioTTM	1.315	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	8.88	1.000	7.82	7.82	[3 - 30]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.15	2.00	4.93	9.85	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.624	1.000	2.93	2.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.247	1.000	7.06	7.06	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.84

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	48.09	1.000	5.24	0	[1 - 100]
returnOnEquityTTM	0.524	2.50	6.97	7.93	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.15	2.00	6.62	9.85	[0 - 30]
dividendYielPercentageTTM	4.69	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
payoutRatioTTM	1.315	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	18.31	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.343	1.000	3.93	0	[0.1 - 0.5]
Total Score				6.92

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.